Longevity has never had a louder year. Every week brings a new molecule, a new at-home test, a new podcast claim that something will add a decade to your life. The actual science is genuinely exciting - we understand senescence, autophagy, mTOR signalling and the epigenetic clock better than ever - but the gap between what is proven in humans and what is sold to humans has rarely been wider. This is Clean Longevity's job: to walk down the 2026 hype list with the same lens we use on supplements, asking for each development what the buzz is, what the evidence actually shows, and what a sensible reader should conclude. The short answer, as ever, is that a few things are real, most are early, and the boring fundamentals still win.
GLP-1 drugs: the real breakthrough, with an asterisk
The buzz. GLP-1 receptor agonists - semaglutide (C187H291N45O59) and the dual agonist tirzepatide (C225H348N48O68) - started as diabetes and weight-loss drugs and are now talked about as the first true "longevity drugs", with claims that they slow ageing itself.
The evidence so far. This is the one place where the hype has hard data underneath it. The SELECT trial randomised more than 17,000 overweight and obese adults without diabetes and found that semaglutide cut major adverse cardiovascular events - heart attack, stroke and cardiovascular death - by about 20% (hazard ratio 0.80) compared with placebo.1 That is a hard clinical outcome in a large randomised trial, which is more than almost any supplement on the market can claim. Signals across cardiometabolic health, kidney function and inflammation point in a consistently favourable direction, and that is why researchers are now openly asking whether the benefits extend to genuine healthspan.
Clean verdict. Real, and important - but read the asterisk. These are prescription drugs with meaningful side effects and cost, tested in people with existing cardiovascular disease, not in healthy adults chasing extra years. They are not supplements, they are not for self-sourcing, and "GLP-1 slows ageing" is still a hypothesis, not a finding. Used appropriately, under medical supervision, this is the most evidence-backed new tool in the cardiometabolic toolkit.
Rapamycin and mTOR: the most studied animal drug, the thinnest human data
The buzz. Rapamycin (sirolimus, C51H79NO13) inhibits mTOR, the central nutrient-sensing pathway, and extends lifespan in essentially every model organism tested. The longevity community treats low-dose intermittent dosing as the closest thing to a proven anti-ageing pill.
The evidence so far. The animal data is the best in the entire field; the human data is not. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) was a 48-week randomised, placebo-controlled study of low-dose weekly rapamycin in normally ageing adults, published in 2025.2 The headline result was sobering: the drug was broadly safe at these doses, but it missed its primary endpoint of reduced visceral fat. Some secondary measures - lean tissue mass and self-reported pain in women on the higher dose - improved, but these are exploratory findings, not proof of an anti-ageing effect.
Clean verdict. Mechanistically the most fascinating story in longevity, and worth watching closely - but in humans we have one modest, largely null trial and no hard outcome data. Rapamycin is also a prescription immunosuppressant with real risks. This is a research frontier, not a self-experiment, and anyone framing weekly rapamycin as settled science is ahead of the evidence.
Taurine: a beautiful mouse story still missing its human chapter
The buzz. A 2023 paper in Science showed that taurine (C2H7NO3S) levels fall with age across species and that taurine supplementation extended lifespan and improved healthspan in mice.3 Headlines promptly declared taurine an anti-ageing nutrient, and it appeared in energy drinks and longevity stacks overnight.
The evidence so far. The mouse and monkey data are genuinely striking, and the link between declining taurine and biological ageing is a real, well-conducted finding. But the crucial human chapter is missing. We do not yet have a randomised controlled trial showing that taurine supplementation extends healthspan or lifespan in people, and the observational human associations cannot prove cause. The authors themselves called for exactly that human trial - it has not reported.
Clean verdict. A compelling lead, not a conclusion. Taurine is cheap and appears safe at typical doses, but "extends life" is a claim that currently rests entirely on animals. Until there is human causal data, taurine belongs in the "promising and unproven" column, not the daily-essentials column. Full breakdown: taurine and longevity after the 2025 studies →
Urolithin A and mitophagy: modest, but actually real
The buzz. Urolithin A (C13H8O5), sold as "Mitopure", is marketed as a mitophagy activator that renews your mitochondria - the clean-up process by which cells recycle worn-out mitochondria - promising more energy and younger muscles.
The evidence so far. This is one of the better-substantiated newer supplements. Human randomised trials have shown that urolithin A improves markers of mitochondrial health and produces measurable gains in muscle endurance and strength, particularly in older and middle-aged adults.4 The effects are consistent and biologically plausible, tied to genuine activation of mitophagy. They are also modest - meaningful improvements in muscle function, not a transformation, and not yet hard longevity outcomes.
Clean verdict. Honest and refreshing: a supplement whose human data roughly matches its claims, as long as you keep the scale realistic. Urolithin A will not reverse ageing, but for muscle and mitochondrial endpoints the signal is real. Of the consumer longevity products in this article, it has among the cleanest evidence-to-hype ratios.
Senolytics: great mechanism, early human trials
The buzz. Senolytics promise to clear "zombie" senescent cells - cells that have stopped dividing but linger and drive inflammation - and so reverse a root cause of ageing. The headline candidates are fisetin (C15H10O6), a plant flavonoid, and the combination of the cancer drug dasatinib with the flavonoid quercetin (C15H10O7). Full deep-dive: do senolytics and “zombie cell” pills actually work? →
The evidence so far. The mechanism is one of the most exciting in ageing biology, and animal data showing that clearing senescent cells improves healthspan is strong. In humans, we are at the very start. Early clinical trials, including work led by groups at the Mayo Clinic, have tested dasatinib plus quercetin and fisetin in conditions linked to cellular senescence, with some encouraging early signals but small numbers and mixed or preliminary results.5 The decisive human trials are still running.
Clean verdict. Promising mechanism, genuinely early evidence. Fisetin is sold as a cheap supplement and dasatinib is a serious prescription chemotherapy agent with real toxicity - neither is ready for casual self-experimentation, and the dosing protocols being copied from podcasts are not validated. Watch this space; do not be the experiment.
Epigenetic clocks: a research tool wearing a consumer costume
The buzz. Mail-in "biological age" tests, built on epigenetic clocks such as DunedinPACE, promise to tell you how fast you are actually ageing and whether your interventions are working.
The evidence so far. Epigenetic clocks are a real and important research advance: measured across large populations, the pace of ageing they capture correlates with disease and mortality risk, and they are reshaping how ageing studies are designed. The problem is the leap from population research tool to personal dashboard. Individual at-home results can vary noticeably between samples and over short timeframes, and a single "biological age" number can shift for technical reasons that have nothing to do with your health. The clocks were built to study groups, not to guide one person's monthly decisions.6
Clean verdict. Fascinating science, oversold product. By all means find it interesting, but do not reorganise your life - or your spending - around a consumer biological-age readout whose individual reliability is still shaky. It is a research instrument, not a bathroom scale for ageing.
NAD+ precursors: the biomarker moves, the outcomes do not
The buzz. NMN (C11H15N2O7P) and nicotinamide riboside (NR) are sold as the way to restore declining NAD+ - a coenzyme central to energy metabolism that falls with age - and so reverse cellular ageing.
The evidence so far. The first half of the claim holds up: human trials from 2024 to 2026 consistently show that NMN and NR raise blood NAD+ levels and are generally well tolerated.7 The second half does not yet. Raising the biomarker has not reliably translated into improvements in hard clinical outcomes - strength, metabolic disease, function or longevity - in well-controlled human studies. The trials that exist are mostly short, small and focused on surrogate markers.
Clean verdict. The textbook example of the longevity field's favourite trap: a real biochemical effect dressed up as a proven health benefit. Higher NAD+ is not the same as a longer, healthier life. As of 2026, NAD+ precursors remain promising but unproven, and the marketing is far ahead of the outcomes.
What a clean longevity reader should actually do in 2026
Strip away the molecules of the moment and the highest-return actions are unchanged, unglamorous, and free or cheap:
- Build and keep muscle. Strength training two to three times a week protects function, metabolism and independence - the single most reliable healthspan lever there is.
- Move daily and protect cardiorespiratory fitness. Fitness is one of the strongest predictors of how long and how well you live, ahead of any pill in this article.
- Eat for fibre and protein, mostly whole foods. The dietary pattern still beats the supplement stack on every hard outcome.
- Sleep properly and manage stress. Boring, free, and more evidence-backed than most of 2026's headlines.
- Do not smoke, keep blood pressure and metabolic health in range, and see a doctor about real cardiometabolic risk - which is exactly the territory where GLP-1 drugs, used appropriately, now genuinely help.
- Treat everything else as optional experiments, not essentials - and never self-source prescription drugs like rapamycin or dasatinib.
Watch this space. The next few years should deliver the readouts that actually matter: larger human trials of rapamycin and senolytics, the first proper taurine trial in people, and whether GLP-1 benefits really extend from the heart to ageing itself. When the evidence arrives, we will update this map. Until then, the cleanest move in a loud field is to know the difference between a breakthrough and a press release.
Common questions
By the strength of the evidence, it is the GLP-1 receptor agonist class. The SELECT trial showed semaglutide (C187H291N45O59) cut major cardiovascular events by about 20% in overweight and obese adults without diabetes - a hard human outcome in a large randomised trial, far ahead of any supplement on the longevity shelf. The important caveat is that these are prescription drugs with side effects, not something to self-source, and they were tested for cardiovascular disease, not lifespan extension in healthy people.
Not yet, on the current evidence. The PEARL trial of low-dose rapamycin (C51H79NO13) found it broadly safe over a year but missed its primary endpoint, with only some secondary signals. Taurine (C2H7NO3S) extended lifespan in mice and declines with age, but there is no human trial showing it extends healthspan or lifespan. Both are interesting research stories, not established interventions, and rapamycin is a prescription immunosuppressant that should never be self-experimented with.
They are useful research tools being sold as consumer products before they are ready for personal decisions. Epigenetic clocks such as DunedinPACE can track ageing patterns across populations, but individual at-home results can vary noticeably between samples and over short periods, and a single biological-age number can move for reasons unrelated to your health. Treat them as an interesting experiment, not a dashboard to optimise.
Human trials of NMN (C11H15N2O7P) and NR reliably raise blood NAD+ levels and are generally well tolerated, but they have not yet produced convincing improvements in hard clinical outcomes. Raising a biomarker is not the same as living longer or better. As of 2026 the honest verdict is that NAD+ precursors remain a promising but unproven category.
Read next: Does Ozempic slow aging? · The Short List of Supplements That Actually Work · The Longevity Hype Detox · Tyrosine and Lifespan
References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. PubMed: 37952131. doi:10.1056/NEJMoa2307563
- Konopka AR, Lamming DW, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025. PMC12074816. medRxiv preprint
- Singh P, Gollapalli K, Mangiola S, et al. Taurine deficiency as a driver of aging. Science. 2023;380(6649):eabn9257. PubMed: 37289866. doi:10.1126/science.abn9257
- Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in adults. Cell Rep Med. 2022;3(5):100633. PubMed: 35584623. doi:10.1016/j.xcrm.2022.100633
- Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin (Mayo Clinic). EBioMedicine. 2019;47:446–456. PubMed: 31542391. doi:10.1016/j.ebiom.2019.08.069
- Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420. PubMed: 35029144. doi:10.7554/eLife.73420
- Nadeeshani H, Li J, Ying T, Zhang B, Lu J. Nicotinamide mononucleotide (NMN) as an anti-aging health product – promises and safety concerns in human trials. J Adv Res. 2022;37:267–278. PubMed: 35499054. doi:10.1016/j.jare.2021.08.003
Study data sourced via PubMed and ClinicalTrials.gov.